TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
WuXi XDC Cayman, Inc. ( (HK:2268) ) has provided an update.
WuXi XDC Cayman, Inc. reported significant financial growth for the first half of 2025, with revenue increasing by 62.2% to RMB2,700.9 million and gross profit rising by 82.2% to RMB975.2 million. The company’s net profit attributable to owners also saw a 52.7% increase, reaching RMB745.7 million. Despite these positive results, the Board has decided not to recommend any interim dividend payment for this period.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$28.20 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman, Inc. operates in the pharmaceutical industry, focusing on the development and production of innovative drug solutions. The company is known for its comprehensive services in drug development and manufacturing, catering to a global market.
Average Trading Volume: 5,754,419
Technical Sentiment Signal: Buy
Current Market Cap: HK$74.98B
For detailed information about 2268 stock, go to TipRanks’ Stock Analysis page.